CEACAM5 and neoplasm: Low expression was significantly related to ECOG performance status 1 (p = 0.036), diabetic patients (p = 0.004), ILC (p = 0.004), stage IV (p = 0.001), the presence of metastasis (p < 0.001), widespread metastasis (p < 0.001), the tumor grade III (p = 0.041), the pathological tumor status T3 (p < 0.001), the pathological node status N3 (p < 0.001), the triple-negative subtypes (p < 0.001), relapsed cases (p < 0.001), died cases (p < 0.001), and cases with high CEA and CA15-3 levels (p < 0.001), as shown in (Table 4, Table 5 and Fig. 1 a & b).